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Abstract
Aims—The EORTC QLQ-C30 is one of the most commonly used measures in cancer but in its
current form cannot be used in economic evaluation as it does not incorporate preferences. We
address this gap by estimating a preference-based single index for cancer from the EORTC QLQ-
C30 for use in economic evaluation.
Methods—Factor analysis, Rasch analysis and other psychometric analyses were undertaken on
a clinical trial dataset of 655 patients with Multiple Myeloma to derive a health state classification
from the QLQ-C30 that is amenable to valuation. A valuation study was conducted of 350
members of the UK general population using ranking and time trade-off. A series of regression
models were fitted to the data, including the episodic random utility model (RUM) to derive
preference weights for the classification system.
Results—The resulting health state classification system has 8 dimensions (physical functioning,
role functioning, social functioning, emotional functioning, pain, fatigue and sleep disturbance,
nausea, and constipation and diarrhoea) with 4 or 5 levels each. Mean and individual level additive
multivariate regression models were estimated and compared. Mean absolute error ranges from
0.050 to 0.054 with no systematic errors. All models have few inconsistencies (0 to 2) in estimated
preference weights.
Conclusions—It is feasible to derive a preference-based measure from the EORTC QLQ-C30
for use in economic evaluation, but this work needs to be extended to other countries and
replicated across other conditions.
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Introduction
Generic preference-based measures, such as the EQ-5D (Brooks, 1996), HUI3 (Feeny et al,
2002) or SF-6D (Brazier et al, 2002) are widely used to calculate quality-adjusted life years
(QALYs) (Drummond, 1994) for use in economic evaluation. The EQ-5D is the most
common generic preference-based measure (PBM) and is currently recommended by NICE
(NICE, 2008). However, generic measures of health have been found to be inappropriate or
insensitive for some medical conditions (Brazier et al, 2007) and for cancer in particular
(Garau et al, 2009). Furthermore, clinicians and researchers often choose to include
condition-specific measures such as the EORTC QLQ-C30 in trials rather than generic
preference-based measures because they need measures which are sensitive to the effects of
interventions across a range of relevant symptoms, side effects and aspects of functioning
and quality of life. Condition-specific measures, such as the EORTC’s core quality of life
questionnaire, the QLQ-C30, have great clinical utility because they summarise a number of
symptom and domain-specific scales. However, because they are not preference-based, they
provide a description rather than a valuation of health, and therefore cannot be used to
estimate QALYs.
There are three ways in which researchers can estimate QALYs for a trial where a generic
preference-based measure such as the EQ-5D is unavailable: undertake ‘mapping’; value
vignettes that describe the health states covered by patients in the trial; or derive a
preference-based measure from the existing condition-specific measure.
Mapping (also known as ‘cross-walking’ or estimating exchange rates between instruments)
involves predicting the relationship between the non-preference-based measure, for example
the EORTC QLQ-30, and a generic preference-based measure, for example the EQ-5D,
using statistical association. Mapping by statistical association may be considered less
arbitrary than using the judgement of ‘experts’ to map between measures. Typically
mapping by statistical association uses two datasets; an estimation dataset that contains
respondents’ self-reported scores for their own health using, for example, EORTC QLQ-C30
and EQ-5D and the study dataset that contains only EORTC QLQ-C30. A statistical
relationship between the EORTC QLQ-C30 and EQ-5D is estimated using regression
techniques on the estimation dataset and the results are applied to the study dataset to obtain
predicted EQ-5D health state utility values. Mapping is a second best alternative to the use
of a preference-based measure directly in the study as mapped estimates can have large
errors, most noticeably when mapping from condition-specific measures to generic
preference-based measures (Brazier et al, 2009). Mapping requires a degree of overlap
between the descriptive systems of both measures, that the relationship estimated in the
estimation dataset is generalisable to the study dataset, and that both measures are
administered on the same population. Yet this means that mapping is valid only if both
measures are appropriate for the patient population, which is unlikely to be the case for
generic preference-based measures administered to cancer patients (Garau et al, 2009).
An alternative solution to estimate QALYs when generic preference-based measures are
unavailable or inappropriate is to value a selection of bespoke descriptions or ‘vignettes’ that
describe the health states covered by patients in the trial. However patients in the trial
experience a variety of different health states and as only a selection will be valued this will
not fully take into account variation across individuals and across treatments. It is also
unlikely that identical health states are experienced in trials for different treatments and
hence vignettes need to be created and valued for each trial which reduces comparability
across trials and treatments.
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It has therefore been argued that a better approach in many cases would be to develop a
preference-based measure from the condition-specific questionnaire specifically designed
for that condition (Brazier and Dixon, 1995). Typically this requires reducing the length of
the questionnaire to obtain a health state classification system that remains responsive and
valid for the condition but that is amenable to valuation. Preference weights for the health
state classification are then obtained from a representative sample of the general population.
This study applies the methods originally developed in the estimation of a generic
preference-based measure of health from the SF-36 (Brazier et al, 1998; 2002) and
subsequently used with condition specific measures in urinary incontinence (Brazier et al,
2008), asthma (Yang et al, 2007; Young et al, 2007) and overactive bladder (Yang et al,
2009; Young et al, 2009a). The study involved three stages. Firstly, a health state
classification system was derived from the EORTC QLQ-C30 that is amenable to valuation
using a recognised preference elicitation technique. The classification system was derived
using psychometric analysis, factor analysis and Rasch analysis on a dataset of patients with
Multiple Myeloma. Secondly a valuation survey was conducted asking members of the
general population to value a sample of states defined by the classification. Thirdly
regression models were estimated on the results of the valuation survey to estimate the
preference weights to produce a utility estimate for every health state defined by the
classification system.
EORTC QLQ-C30
The EORTC QLQ-C30 is one of the most commonly used measures in cancer (Aaronson et
al, 1993) and dominates cancer clinical trials in Europe and Canada. The EORTC QLQ-C30
contains 30 questions that cover the most common symptoms of cancer (such as pain,
fatigue, nausea and vomiting) and various aspects of function (including physical, role,
social, emotional and cognitive functioning). The EORTC QLQ-C30 is summarized using
fourteen scales, each representing a particular symptom or aspect of function, plus one
global quality of life scale (based on two global questions). Its validity has been well
established for many conditions in cancer.
While the EORTC QLQ-C30 has proved to be a useful instrument for demonstrating
treatment benefits, it cannot be used in economic evaluation in its current form because it
does not incorporate preference information. While it generates a profile of scores
representing a range of symptoms and aspects of functioning and a global quality of life
score, it does not currently generate a single preference-based index of quality of life
required for economic evaluation using QALYs. Further, the number of items and scales is
too large to be amenable to valuation using preference elicitation techniques such as time
trade off and standard gamble.
EORTC QLQ-C30 Multiple Myeloma patient dataset
The dataset used to derive the health state classification system contains patients with
Mutiple Myeloma collected in a randomized controlled trial, Phase III VISTA trial (FDA
number…) undertaken in 2007 (Sabine can you provide correct info please). Patients were
asked to complete the EORTC QLQ-C30 at screening, each cycle of treatment (cycles 1–9),
end of treatment and post treatment (cycles 1–17). The screening phase of the dataset
(n=655) is used to select items for the health state classification. Data from cycle 5 of
treatment in the trial is then used to validate the choice of items. This study forms part of a
wider cross-country study across different cancer patient groups and the health state
classification will be validated using datasets of patients with different types of cancers.
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Methods
Methodology used to derive a health state classification from the QLQ-C30
The aim was to produce a multidimensional health state classification from the EORTC
QLQ-C30 that is amenable to valuation by respondents with a minimum loss of information
and subject to the constraint that responses to the original instrument can be unambiguously
mapped onto it. This implies that the text of the items should be altered as little as possible.
The task is therefore to determine the dimensions, items and the levels of the EORTC QLQ-
C30 to be included in the new classification. The methodology outlined here uses a
combination of Rasch and classical psychometric analysis (Young et al. 2009a). SPSS
version 15 (SPSS Inc, 2005) was used for the factor analysis and Rasch Unidimensional
Measurement Models (RUMM2020) (RUMM Laboratory Pty Ltd, 1997–2004) was used for
the Rasch analysis.
Dimensional structure—Multidimensional health state classifications should have
structural independence between dimensions to avoid nonsensical states (Feeny et al, 2002).
In other words, there must be little correlation between the dimensions in our classification
system. The large literature on the EORTC QLQ-C30 focuses upon its use as a profile
measure of health, but here we wish to determine the dimensions across all items, ignoring
whether these are functions or symptoms.
Factor analysis can be used for a set of observed variables to identify structurally
independent dimensions by highlighting underlying factors that explain patterns of
correlation (Chatfield and Collins, 1980). We applied factor analysis to 27 of the 30 items of
the EORTC QLQ-C30, (excluding global quality of life and financial impact items as these
are inappropriate for a PBM of HRQoL) to explore the dimension structure of the EORTC
QLQ-C30. The dimensions were determined using a varimax component matrix and
eigenvalues. The extent to which items belong to a single dimension can also be examined
using Rasch analysis (see below). The results were discussed with our team’s clinical expert
(GV) to make sure that they made sense clinically before making a final decision on the
dimensionality of the health state classification.
Item selection—Each dimension of a health state classification system of a preference-
based measure is usually represented by just one or two items to render the system amenable
to preference elicitation methods. We used the following conventional psychometric criteria
to help select items from the QLQ-C30: distribution of responses across categories of
response (including floor effects and ceiling effects), the percentage of missing data,
correlation of item to dimension, and responsiveness to change over two points in time using
the standardised response mean (SRM).
A further technique often used (Young, 2007, 2009a, 2009b; Mavranezouli, 2009) to select
items is Rasch analysis (Rasch, 1960). This is a mathematical technique that converts
qualitative (categorical) responses to points on a continuous (unmeasured) latent scale using
a logit model (Tesio, 2003). It can be used to assess whether an item fits the model, the
severity of health problem being covered by each item, the extent to which items have
response choices that are appropriately ordered as responders can distinguish between the
response levels for a given item and whether items perform differently between populations
(known as differential item functioning (DIF)) (Young et al, 2009). Items that fit the Rasch
model, cover the full range of severity, have ordered response choices and do not suffer
from DIF were considered as candidates for inclusion in the health state classification. Items
that did not fit the Rasch model (using criteria that item level Chi-square P-value<0.01) were
removed; all other items were retained and the Rasch analysis was re-estimated. We used the
following criteria to assess the Rasch model for each dimension: item-trait interaction
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(whether data fitted the Rasch model for groups of responders with similar underlying
health); person separation index (PSI) (whether the Rasch model could discriminate between
responders); item fit and person fit residuals (the divergence between expected and observed
responses per respondent); and item range and spread at logit zero (whether items covered a
wide range of severity).
The final selection of dimensions, items and levels for the health state classification was
based on what appeared to perform best using the psychometric tests and Rasch analysis and
at the same time ensuring that health states made clinical sense and were amenable to
valuation by respondents. The process involved judgment by our clinical expert (GV) and
consideration of other factors such as wording of the health state classification system.
Valuation study to obtain preferences for the health state classification
The second stage of the research was to obtain valuations of states defined by the health
state classification system. Key methodological issues were the choice of technique for
eliciting preferences, the sample of states valued, sampling of respondents and overall size
of sample.
The main valuation technique used to value health states was Time Trade-off (TTO). States
were sampled using an orthogonal array in order to enable the estimation of an additive
model for the preference weights. Use of an orthogonal array to sample states is common
when dimensions are independent. SPSS version 15 was used to produce a sample of 81
states using orthogonal array and this was supplemented by 4 additional states. We chose to
value 85 states in order to enable each respondent to value the worst state, an equal number
of responses per state, and an equal number of states to be valued per respondent.
At the interview, respondents read the descriptive system and self-completed the system for
their own health. The EORTC QLQ-C30 does not mention cancer in its descriptive system
and therefore respondents were not aware that the health states were used to describe the
health-related quality of life of cancer patients. Respondents were asked to rank 8 states
alongside ‘full health’ and ‘dead’ to help familiarize them with the states. Respondents then
valued the same 8 states using the Measurement and Valuation of Health (MVH) study
version of TTO that involves the use of a visual prop designed by the MVH group
(University of York) (see Dolan, 1997). Respondents were initially taken through a
hypothetical TTO to help them understand the task. For each health state respondents were
first asked whether they would prefer the given health state for 10 years or to die
immediately. For health states considered better than being dead (BTD), respondents were
asked to choose between (a) health state h for w years, after which they will die, or (b) full
health for z years (z ≤ w), after which they will die. While w is fixed at 10 years, years in
full health, z, is varied to determine the point where respondents are indifferent between the
two options. For health states considered worse than being dead (WTD) respondents were
asked to choose between (a) health state h for w years followed by full health for z years
after which they will die, or (b) immediate death. Both years in optimal health, z, and years
in health state, w=10-z, are varied to determine the point where respondents are indifferent
between the two options. After the collection of trade-off responses (w, z), respondents were
asked a number of background questions covering demographic and socio-economic
characteristics.
A representative sample of the general population was interviewed in their own home by
trained and experienced interviewers who had worked on numerous previous valuation
surveys, such as the HUI2 (McCabe et al, 2005) and OAB-5D (Yang et al, 2009).
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The valuation data
Respondents were from the geographical areas in the North of England including urban and
rural areas with a mix of socio-economic characteristics. There were 350 successfully
conducted interviews, a response rate of 40.3% for suitable respondents answering their
door at time of interview. Six respondents were excluded from the analysis; three were
excluded for valuing all states as identical and less than one; two respondents were excluded
for valuing the worst possible health state higher than every other state; one respondent was
excluded for valuing all states as worse than dead. All other responses were used in the
analysis reported here. The remaining 344 respondents had a health state completion rate of
98.5% in the TTO tasks. Characteristics of the included respondents are compared to the
general population in South Yorkshire and England (Table 1). The valuation sample
contained a higher proportion of people aged 41–65, retired people, more females and more
people in poorer health than in the population at large.
Modelling to obtain preference weights for the health state classification
The TTO responses (z, w) were analysed using a range of different specifications. The
standard specification is based on the approach first used for the UK EQ-5D preference
weights (Dolan, 1997):
(1)
Where i=1,2 … n represents individual health states and j=1,2…m represents respondents.
The dependent variable  is disvalue for health state i valued by respondent j and Xδλ is a
vector of dummy explanatory variables for each level λ of dimension δ of the health state
classification. Level λ = 1 acts as a baseline for each dimension.
The second specification is the episodic random utility model (ERUM), where the value of
the health state depends on its duration, wij:
(2)
In order to produce error terms on the same scale as the standard specification in equation
(1), both zij and wij are divided by 10 before estimation.
The standard approach transforms WTD TTO responses to be bound at −1. This has been
criticised as there is little empirical evidence for why values should be bound at −1 and
arguably the transformed responses cannot be interpreted as being measured on the same
utility scale as states BTD (Patrick et al, 1994). The ERUM model was developed to deal
with this criticism by changing the way TTO responses are modelled. Under the ERUM,
WTD TTO responses are not transformed and are therefore modelled in a way that is
consistent with BTD responses (Craig and Busschbach, 2009).
Each model was estimated using ordinary least squares (OLS) estimation, which assumes
that each observation is independent, regardless of the fact that there will be on average 8
observations per individual. Random and fixed effects were estimated to take into account
within and between respondent variation, allowing for the fact that there are multiple
observations per individual (Brazier et al, 2002). For the random and fixed effects model the
error term, εij is subdivided as follows:
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(3)
Where uj is individual random effect and eij is the usual random error term for the ith health
state valuation of the jth individual, assumed to be random across observations. Maximum
likelihood estimation was used for the estimation.
Instead of examining individual responses, the TTO responses for each state may be
condensed into mean estimates and the standard model (equation 1) can also be estimated
using mean level data:
(4)
Where ȳi represents mean TTO disvalue of the ith health state, i=1,2 …, 86 health states
averaged across all individuals who valued the ith health state, and εi is the error term.
Estimation was via OLS on a dataset of 86 observations. The impact of adding interaction
terms and socio-demographic variables is explored for all models.
Several alternative criteria to indicate model performance are reported. The difference
between actual and predicted values is assessed using mean absolute error (MAE) calculated
at the health state level. MAE is an indicator of how large the prediction errors are and
reporting the number of health states valued with errors greater than 5% and 10% indicates
whether the errors are of a minimal important difference. Inconsistencies in parameter
estimates for adjacent levels of an item were noted as these indicated that worsening health
did not lead to a lower utility value. Models in which these inconsistencies were removed by
merging levels were also estimated. The number of main effects with insignificant
coefficients is also reported. Performance of all regression models is reported using
inconsistencies, significant coefficients, mean absolute error of health state predictions and
MAE greater than 5% and 10% and by examining plots of actual and predicted health state
values.
Results
Health state classification
Step 1: Instrument dimensionality—A four factor model on all 27 items accounted for
58.7% of the variance. Items were divided into the four factors according to their ‘loadings’,
the correlation between the item and the factor. All items loaded >0.35 on a factor, but some
items cross loaded. Factor 1 contained the majority of items (14), covering physical
functioning, role functioning, social functioning, pain and items ‘need a rest’, ‘felt weak’
and ‘difficulty concentrating’. Factor 2 contained all items covering emotional functioning
plus ‘trouble sleeping’. Factor 3 contained all items covering eating and digestion and factor
4 contained items ‘short of breath’, ‘were you tired’ and ‘difficulty remembering’. Items
loading into factors 2 and 3 were conceptually clear and in accordance with the grouping of
the original EORTC instrument. Items loading into factors 1 and 4 (17 items), on the other
hand, covered a large range of concepts and further factor analysis was done on these items
to determine whether further differentiation was possible. The additional item ‘trouble
sleeping’ was added (18 items in total) over a concern that the initial factor analysis captured
some causality rather than correlation.
A four factor model on the 18 items explained 67.6% of the variance. All items loaded >0.4
on a factor, but some items cross loaded (difference between cross loadings <0.2). Cross
loading items were included in the factor that was clinically meaningful. The four factors
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were: physical functioning, role functioning and pain; social functioning; fatigue, trouble
sleeping and short of breath; cognitive functioning (principal-component rotated factor
loadings are available from authors on request).
Table 2 shows the potential items categorised according to the dimensions for consideration
for the measure amenable to valuation. Overall the 27 items can be divided into 6 factors or
dimensions: (1) physical functioning, role functioning and pain, (2) social functioning, (3)
emotional functioning, (4) digestion, (5) fatigue, trouble sleeping and shortness of breath
and (6) cognitive functioning. After consultation with our clinical specialist (GV), cognitive
functioning (items 20 and 25) and shortness of breath (item 8) were excluded from the PBM
on the grounds that they are neither a symptom nor side effect of treatment for Multiple
Myeloma, leaving 24 items remaining. The remaining five dimensions are used for the
following analysis to determine the PBM, where items were fitted to Rasch models for each
of the five dimensions.
Step 2: Selecting items by dimension—Table 2 presents psychometric analysis and
goodness of fit for the Rasch models for each dimension.
Item-level ordering and differential item functioning: Only item 15 (digestion
dimension) was disordered and for this item ‘a little’, ‘quite a bit’ and ‘very much’ were
collapsed into one level prior to proceeding with further Rasch modelling. Four items
demonstrated differential item functioning by sex and were split according to sex: items 1
and 3 (physical functioning, role functioning and pain dimension), item 15 (digestion) and
item 22 (emotional functioning). Item 21 (emotional functioning) demonstrated differential
item functioning by age and was split according to age. This indicated that these items were
not ideal for the health state classification.
Rasch model goodness of fit: Three items demonstrated poor item fit (Chi-square P-
value<0.01) and were excluded from subsequent Rasch models estimated for each
dimension: item 6 (physical functioning, role functioning and pain dimension), item 14
(digestion), item 11 (fatigue).
Physical functioning, role functioning and pain: This dimension covers three separate
attributes of quality of life: physical functioning, role functioning and pain. Each item covers
only one attribute and it is unlikely that an item on physical functioning, for example, will
capture or reflect role functioning or pain. In order to accurately represent the entire
dimension, and in accordance with the EORTC QLQ-C30 scaling and with clinical opinion,
we decided that a minimum of one item each for physical functioning, role functioning and
pain was required.
Out of the 5 items that capture physical functioning, items 4 and 5 did not capture the full
range of severity but had the highest SRM suggesting better responsiveness and ability to
capture severe health problems, though in all cases they were low according to Cohen’s
criteria (Cohen, 1978). Item 2 overall performed well with relatively high item fit but had
floor effects, relatively low SRM and limited range of severity. Figure 1 shows the item map
for all items in this dimension, reporting three thresholds between response categories “not
at all’ and ‘a little’, ‘a little’ and ‘quite a bit’, and ‘quite a bit’ and ‘very much’. No item
captured the full severity range in terms of coverage as items 3, 4 and 5 captured severe
health whereas items 1 and 2 captured less severe health. Given that none on the items were
ideal, items 2 and 3 were chosen in order to cover the full severity range and there is a
coherence since both measure trouble walking. Items 2 and 3 were merged to a five level
item in the health state classification, with levels 1 to 4 taken directly from item 2 (no/a
Rowen et al. Page 8
Value Health. Author manuscript; available in PMC 2013 October 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
little/quite a bit/very much trouble taking a long walk) and level 5 (very much trouble taking
a short walk outside of the house) taken from level 4 of item 3.
Of the two role functioning items, item 7 had ceiling effects, but also had good Rasch model
item fit and relatively good item range (Figure 1). Item 6 performed similarly to item 7 for
the psychometric analysis, but had poor Rasch model item fit. Therefore item 7 was selected
for the health state classification to represent role functioning.
Items 9 and 19 capture pain. Item 9 had a large severity range, but poor item fit, very high
item fit residual and low item level p-value suggesting the item contributes poorly to the
dimension. Item 19 had a more limited range and higher ceiling effects but better item fit.
Item 19 was chosen due to better item fit and due to its wording, since it measures the extent
to which pain interferes with daily activities rather than the existence of pain per se, which is
likely to be more important to respondents.
Social functioning: Of the two social functioning items, item 26 had a slightly higher
degree of ceiling effects, higher item fit residual and lower p-value. Further, it may not be
applicable to all respondents as it captures whether physical condition or medical treatment
interferes with family life. Item 27 was chosen as it performs marginally better
psychometrically and is arguably applicable to a higher number of respondents as it
measures interference with social activities.
Emotional functioning: Items 21 and 22 suffered from DIF. Items 23 and 24 performed
similarly across all criteria. Item 23 had a larger severity range than item 24, but also had a
higher item fit residual, suggesting greater divergence between expected and observed
responses. Item 24 was chosen as it overall performs best, had a higher SRM and was felt to
be more clinically relevant to patients with cancer.
Digestion: None of the digestion items performed well in psychometric or Rasch analysis.
Despite this they were included in the health state classification as it was felt that they were
clinically important for patients with Multiple Myeloma. These items capture multiple
symptoms of digestion-related problems: lack of appetite, nausea, vomiting, constipation
and diarrhoea. Lack of appetite, nausea and vomiting (items 13, 14, 15) are all closely
related symptoms, and constipation and diarrhoea (items 16 and 17) are bowel symptoms,
suggesting the items can be separated into two attributes. Item 13 was the only item from
appetite, nausea and vomiting that did not suffer from DIF, item level disordering or poor
item fit. However, this item performed poorly in the Rasch model with small coverage at
logit zero and high item fit residuals. After consultation amongst our research team,
including our clinical specialist, it was decided that item 13, which captures lack of appetite,
would not be chosen because it maybe thought to be a desirable (positive) symptom by some
people and may be a symptom due to the age of the population rather than the condition.
Therefore, despite suffering from problems in the Rasch model items 14 and 15 were
considered as it was felt to be important to capture appetite, nausea or vomiting in the health
state classification. Both items suffer from high ceiling effects and have low SRM, with item
14 performing marginally better. Therefore item 14 (nausea) was chosen for the health state
classification.
Items 16 and 17 on constipation and diarrhoea perform similarly, both suffering from
extreme ceiling effects, small spread at logit zero and high residuals. It was decided to
combine these items as they are both bowel symptoms where respondents rarely suffer from
both during a weekly period. The items were combined such that level 1 of the merged item
captures no bowel (constipation or diarrhoea) problems, levels 2, 3 and 4 capture ‘a little’
‘quite a bit’ and ‘very much’ constipation and/or diarrhoea.
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Fatigue and sleep disturbance: Items 10, 12 and 18 performed similarly in the Rasch and
psychometric analyses, with large severity range and no large ceiling or floor effects.
However item 10 had a relatively high item fit residual and item 12 has a low item p-value
indicating it does not contribute well to the dimension in Rasch models. Item 18 performed
marginally better, with a relatively high p-value, low residual, large coverage at logit zero
and large range, and so was selected for the health state classification.
Health state classification: The classification system has 8 dimensions made up of 10
items. Table 4 summarises the items chosen from the EORTC QLQ-C30 for each dimension
of the health state classification. Table 5 presents the final health state classification system
of dimensions and their levels. A health state is made up of 8 sentences and hence has an 8
digit identifier, from best state 11111111 to worst state 54444444. This system generates a
total of 81,920 health states.
Valuation survey
Table 6 presents mean descriptive statistics for observed TTO values (generated using the
formula from Dolan, 1997) for all 86 states included in the valuation survey. Mean TTO
values varied from 0.95 for best state to 0.13 for worst state, meaning that on average all
states were valued as better than being dead. Of the total 2710 TTO observations, 514
observations (19%) were equal to 1 (equivalent in value to full health) and 271 (10%) were
less than or equal to 0 (valued as the same or worse than being dead).
Modelling health state values
Table 7 presents the preference weights estimated using a variety of regression models. All
coefficients have the expected sign (i.e., level 1 on each dimension is the reference point and
higher levels increase TTO disvalue), their size is consistent with the severity scale in all but
two cases (i.e., higher levels have larger coefficients and an increasing increment on TTO
disvalue except physical functioning levels 4 and 5 and nausea levels 2 and 3) and the
majority of coefficients are statistically significant. Models (1), (2), (4) and (5) are based on
the standard specification outlined in equations (1) and (4), model (3) uses the ERUM
specification in equation (2). Models (1) and (3) are individual level models estimated using
OLS, model (2) is a random effects model estimated using maximum likelihood (the results
of the Hausman test confirmed that a fixed effects model was not appropriate) and models
(4) and (5) are mean level models. Model (5) is a consistent version of model (4) where
adjacent inconsistent levels are merged into a common dummy variable.
Mean absolute error was similar between models ranging from 0.046 to 0.054. The number
of health states with errors greater than 5% ranges from 33 to 41 and errors greater than 10%
ranges from 6 to 13. Models including interaction effects and socio-demographic were
estimated (available from the authors by request) but predictive ability, inconsistencies and
significant coefficients for the main effects variables were not improved.
Discussion
We have estimated a preference-based measure for the EORTC QLQ-C30 using
methodology first applied in the development of the SF-6D from the SF-36 (Brazier, 2002)
and a number of condition specific measures. The EORTC-8D was constructed using
psychometric analysis (including Rasch) to ensure that chosen items appropriately reflected
their dimension and that each dimension covered a wide range of severity. A sample of
states was valued and then the results of the survey modeled using a variety of methods,
including a new ERUM method. This enables utility scores to be generated directly from
EORTC QLQ-C30 datasets.
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An important concern is that often condition-specific measures fail to capture co-morbidities
and side-effects of treatments, and hence are not strictly comparable to generic measures
when used to estimate QALYs for resource allocation. One way to enhance comparability
across measures is for all measures to use the same methodology to derive values (Brazier et
al, 2007). Our valuation study followed the methodology used in the development of generic
measures: we implemented the protocol used to derive the UK EQ-5D preference weights
(Dolan, 1997); used common anchors of 1 for full health and zero for dead; and interviews
were conducted using a sample of the general population. Furthermore the EORTC-8D
descriptive system captures a wide range of dimensions including generic dimensions such
as physical functioning and role functioning, as well as more condition-specific symptoms
such as nausea, constipation and diarrhoea. This means that the descriptive system is likely
to capture overall health-related quality of life including both comorbidities and side-effects.
Indeed, as the EORTC-8D has few condition-specific functionings and symptoms the
measure may not be sufficiently sensitive to measure health-related quality of life of cancer
patients. An area of future research will be to compare the measure to generic measures in
terms of sensitivity and validity.
Given that the health state classification measures cancer it is somewhat surprising that all
states have a positive mean TTO value and hence at the aggregate level all states are valued
as being better than being dead. This is contrast to other valuation studies such as the UK
EQ-5D valuation study where 38% (16/42) of health states valued were on average valued
as being worse than dead (with mean TTO below zero). One hypothesis is that respondents
would view the states differently if cancer was included in the health state description, and
this is a topic for future research.
The final preferred model estimating preference weights should have no inconsistencies;
health state utility values should always decrease as health states become more severe. The
main inconsistency was observed for physical functioning levels 4 and 5. This may have
been due to the merging of 2 items in the EORTC QLQ-C30 to form this dimension. Models
(3) and (5) perform best overall according to the criteria of predictive ability, inconsistencies
and significant coefficients, with model (3) performing better using all criteria. Model (5)
has a predicted range of utilities from 1 to 0.199 whereas model (3) has a predicted range of
1 to 0.291, meaning that the worst state defined by the classification has a much lower value
using preference weights estimated using model (5). Deciding upon the preferred model
comes down to a choice between the mean model (5) with no inconsistencies, as chosen
both in the valuation of the SF-6D (Brazier and Roberts, 2004) and the overactive-bladder-
specific measure (Yang et al, 2009), or the recently developed technique of the ERUM.
Although model (5) is in accordance with the recommended value set of many similar
measures, the ERUM model (3) is here the preferred model as it more appropriately deals
with TTO values for SWD and performs best.
The EORTC-8D was developed out of a concern that generic measures were not appropriate
to measure the quality of life of cancer patients (Garau et al, 2009). The EORTC-8D enables
QALYs to be directly estimated using the EORTC QLQ-C30, a questionnaire typically
included in cancer trials, rather than the use of generic measures that are less appropriate
(Garau et al, 2009) or mapping to generic measures that is both less appropriate and
increases error around utility estimates. It is hoped that this measure will provide appropriate
and useful information for cost per QALY analysis undertaken in cancer trials.
A general concern regarding the development of PBMs from existing questionnaires is that
the classification system is strongly influenced by the specific patient dataset used to
develop the classification. The patient dataset and valuation study used here are both UK
trial datasets and hence the EORTC-8D classification and preference weights presented here
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are most appropriate for UK trials. The health state classification was developed using
Multiple Myeloma patients. Further testing of the classification will be undertaken across
datasets of cancer patients with different types of cancers. This study forms part of a wider
cross-country study that will examine the use of preference-based measures from the
EORTC QLQ-C30 on a variety of countries and different patient groups.
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Figure 1.
Item map for physical functioning, role functioning and pain dimension
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Table 1
Characteristics of respondents
Included respondents (n=344)1 South Yorkshire2 England2
Mean age (s.d.) 47.8 (18.5) NA NA
Age distribution
 18–40 38.6% 41.2% 41.6%
 41–65 42.7% 39.1% 39.1%
 Over 65 17.2% 19.7% 19.3%
Female 61.9% 51.2% 51.3%
Married/Partner 57.0% NA NA
Employed or self-employed 43.6% 56.1% 60.9%
Unemployed 0.6% 4.1% 3.4%
Long-term sick 6.4% 7.7% 5.3%
Full-time student 7.3% 7.5% 7.3%
Retired 24.7% 14.4% 13.5%
Own home outright or with a mortgage 69.2% 64.0% 68.7%
Renting property 29.9% 36.0% 31.3%
Secondary school is highest level of education 41% NA NA
EQ-5D score (s.d.) 0.76(0.34) NA 0.86(0.23)3
TTO completion rate 98.5%
1Six respondents were excluded; three for valuing all states as identical and less than 1; two for valuing the worst possible state higher than every
other state; one for valuing all states as worse than dead.
2Statistics for South Yorkshire Health Authority and for England in the Census 2001. Questions used in this study and the census are not identical.
The census includes persons aged 16 and above whereas this study only surveys persons aged 18 and above. Age distribution is here reported as the
percentage of all adults aged 18 and over.
3
Interviews conducted in the Measurement and Valuation of Health (MVH) study in 1993 (Kind et al, 1999).
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Table 4
Summary of EORTC QLQ-C30 items included in the EORTC-8D descriptive system
EORTC-8D dimension EORTC QLQ-C30 items Question
Physical functioning 2 Trouble taking a long walk
3 Extra level added from ‘trouble taking a short walk’
Role functioning 7 Limited in pursuing hobbies or other leisure time activities
Pain 19 Pain interfere with daily activities
Social functioning 27 Physical condition or medical treatment interfered with social life
Emotional functioning 24 Feel depressed
Nausea 14 Felt nauseated
Constipation and diarrhoea 16 Constipated
17 Diarrhoea
Fatigue and trouble sleeping 18 Tired
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Table 5
EORTC-8D descriptive system
During the past week:
Physical functioning
You had no trouble taking a long walk
You had a little trouble taking a long walk
You had quite a bit of trouble taking a long walk
You had very much trouble taking a long walk
You had very much trouble taking a short walk outside of the house
Role functioning
You were not limited in pursuing your hobbies or other leisure time activities
You were limited a little in pursuing your hobbies or other leisure time activities
You were limited quite a bit in pursuing your hobbies or other leisure time activities
You were limited very much in pursuing your hobbies or other leisure time activities
Pain
Pain did not interfere with your daily activities
Pain interfered a little with your daily activities
Pain interfered quite a bit with your daily activities
Pain interfered very much with your daily activities|
Emotional functioning
You did not feel depressed
You felt a little depressed
You felt quite a bit depressed
You felt depressed very much
Social functioning
Your physical condition or medical treatment did not interfere with your social activities
Your physical condition or medical treatment interfered a little with your social activities
Your physical condition or medical treatment interfered quite a bit with your social activities
Your physical condition or medical treatment interfered very much with your social activities
Fatigue and sleep disturbance
You were not tired
You were a little tired
You were quite a bit tired
You were tired very much
Nausea
You did not feel nauseated
You felt a little nauseated
You felt nauseated quite a bit
You felt nauseated very much
Constipation and diarrhoea
You were not constipated and did not have diarrhoea
You were constipated and/or had diarrhoea a little
You were constipated and/or had diarrhoea quite a bit
You were constipated and/or had diarrhoea very much
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